We are live on ! Find out more
OASM

Oasmia Pharmaceutical AB
OASM

Delisted

OASM was delisted on the 21st of August, 2019.

Back to rankings

4 hedge funds and large institutions have $212K invested in Oasmia Pharmaceutical AB in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more capital invested

Capital invested by funds: $113K → $212K (+$99K)

20% less funds holding

Funds holding: 5 → 4 (-1)

33% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 3

Holders
4
Holders Change
-1
Holders Change %
-20%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CLOS
Compagnie Lombard Odier SCmA
Switzerland
+$69.7K
2
VF
Virtu Financial
New York
+$24.1K
3
Morgan Stanley
Morgan Stanley
New York
+$5.06K
4
UBS Group
UBS Group
Switzerland
+$3.99K

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$54K
2
Jane Street
Jane Street
New York
-$37K
3
OMC
Old Mission Capital
Illinois
-$21K

OASM Hedge Fund Activity: Q3 2018 in Review

4 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Oasmia Pharmaceutical AB (OASM) for Q3 2018, worth a combined $212K — up 88% from $113K a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of OASM and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 2 added.

The largest buyer was Compagnie Lombard Odier SCmA, opening a new position worth an estimated $69.7K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $54K sold.

  • 4 institutional investors held Oasmia Pharmaceutical AB (OASM) as of Q3 2018, down from 5 in Q2 2018.
  • Funds reported $212K of Oasmia Pharmaceutical AB stock for Q3 2018, up 88% quarter-over-quarter.
  • 2 funds opened new Oasmia Pharmaceutical AB positions in Q3 2018 and 3 closed out, a net change of -1 holder.
  • The largest Oasmia Pharmaceutical AB buyer in Q3 2018 was Compagnie Lombard Odier SCmA, an estimated $69.7K added.
  • The largest Oasmia Pharmaceutical AB seller in Q3 2018 was Susquehanna International Group, an estimated $54K sold.

Based on aggregated 13F filings for Q3 2018.